PRKN, first found to be mutated in patients with early-onset Parkinson’s disease, has also been confirmed to carry mutations and deletions in human malignancies including glioblastoma, colon cancer, and lung cancers (Veeriah et al., 2010). Here, PRKN is linked to lung carcinoma.